8-K: DURECT to be Acquired by Bausch Health for $1.75/Share Plus Milestones

DURECT Corporation announced its second quarter 2025 financial results and provided an update on its proposed acquisition by Bausch Health, which includes an upfront cash payment of $1.75 per share and potential milestone payments up to $350 million.

Summary

• DURECT Corporation announced its second quarter ended June 30, 2025 financial results and provided an update on the previously announced acquisition by Bausch Health Companies Inc.
• Under the terms of the Merger Agreement, Bausch Health will pay $1.75 per share of DURECT common stock in an all-cash transaction, representing an upfront consideration of approximately $63 million at closing.
• The transaction includes the potential for two additional net sales milestone payments of up to $350 million in the aggregate, contingent on the achievement of milestones related to larsucosterol sales before the earlier of the 10-year anniversary of its first commercial sale in the United States and December 31, 2045.
• The Merger is expected to be completed in the third quarter of 2025.
• Merger Sub commenced a tender offer on August 12, 2025, to acquire all of DURECT's outstanding shares of common stock.
• Total revenues for the three months ended June 30, 2025, were $447,000, compared to $646,000 for the same period in 2024.
• Net loss for the three months ended June 30, 2025, was $2.3 million, an improvement from a net loss of $3.7 million for the same period in 2024.
• Cash, cash equivalents, and investments were $6.7 million as of June 30, 2025, down from $12.0 million at December 31, 2024.
• Larsucosterol, DURECT's lead drug candidate, is a late-stage epigenetic therapy in clinical development for alcohol-associated hepatitis (AH), which has received FDA Fast Track and Breakthrough Therapy designations.

Sentiment

Score: 6

Explanation: The acquisition provides a clear exit for shareholders with an upfront cash payment and potential upside from milestones, which is positive. However, the company's standalone financial performance shows declining revenues and cash, indicating a need for such a transaction. The upfront cash value might be considered low given the potential of larsucosterol, but the milestone payments offer significant future value if achieved. The overall sentiment is cautiously positive due to the acquisition providing certainty and potential future value, despite current financial weakness.

Positives

• The proposed acquisition by Bausch Health offers DURECT shareholders an upfront cash payment of $1.75 per share, providing immediate liquidity and a premium over recent trading prices.
• Shareholders have the potential to receive significant additional net sales milestone payments of up to $350 million in aggregate, tied to the commercial success of larsucosterol.
• Net loss improved to $2.3 million for Q2 2025, compared to $3.7 million for Q2 2024, indicating improved operational efficiency or reduced expenses.
• Research and development expenses decreased significantly to $1.176 million in Q2 2025 from $2.247 million in Q2 2024.
• Selling, general and administrative expenses also decreased to $2.067 million in Q2 2025 from $2.566 million in Q2 2024.
• Larsucosterol, the lead drug candidate, holds FDA Fast Track and Breakthrough Therapy designations for alcohol-associated hepatitis, highlighting its potential and the urgent medical need it addresses.

Negatives

• Total revenues decreased to $447,000 for Q2 2025 from $646,000 for Q2 2024, representing a 30.8% decline.
• Cash, cash equivalents, and investments significantly declined to $6.7 million as of June 30, 2025, from $12.0 million at December 31, 2024, indicating a substantial burn rate.
• The upfront acquisition price of $1.75 per share, while offering a premium, may be considered low by some investors given the potential future value of a drug candidate with Breakthrough Therapy designation.

Risks

• Uncertainties exist regarding the timing and completion of the Tender Offer and the Merger.
• There are uncertainties as to the percentage of DURECT stockholders who will tender their Company Shares in the Offer.
• The possibility of competing offers being made could complicate the current transaction.
• Various closing conditions for the Offer or the Merger may not be satisfied or waived, including the failure to receive any required regulatory approvals.
• Risks relate to DURECT's liquidity during the pendency of the Offer and the Merger or in the event of a termination of the Merger Agreement.
• There is a risk that the Milestone Payments for larsucosterol are not achieved.
• The transaction may cause disruption, making it more difficult to maintain relationships with employees, collaborators, partners, vendors, and other business partners.
• Diverting management's attention from DURECT's ongoing business operations is a risk.
• Stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense.

Future Outlook

The merger with Bausch Health is expected to be completed in the third quarter of 2025. The prospective performance and outlook of the surviving company's business, performance, and opportunities are subject to various risks, including the achievement of milestone payments for larsucosterol.

Industry Context

This acquisition by Bausch Health reflects a broader industry trend where larger pharmaceutical companies acquire smaller biopharmaceutical firms with promising late-stage drug candidates, particularly those addressing significant unmet medical needs and holding valuable regulatory designations like FDA Fast Track and Breakthrough Therapy. This strategy allows Bausch Health to potentially expand its therapeutic portfolio into acute organ injury with DURECT's epigenetic therapy, larsucosterol, for alcohol-associated hepatitis (AH), a condition with high mortality and limited treatment options.

Legal Proceedings

• Stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense.

Stakeholder Impact

• Shareholders will receive $1.75 per share in cash upfront for their common stock, with the potential for additional milestone payments up to $350 million, providing a defined return on investment.
• Employees, collaborators, partners, and vendors may experience disruption and uncertainty due to the transaction, potentially making it more difficult to maintain existing relationships.
• The acquisition by Bausch Health could provide greater resources and stability for the continued development and potential commercialization of larsucosterol, benefiting patients who could ultimately receive the therapy.

Next Steps

• Completion of the Tender Offer by Merger Sub to acquire DURECT's outstanding shares of common stock.
• Merger of Merger Sub with and into DURECT, with DURECT surviving as a direct or indirect wholly owned subsidiary of Bausch Health.
• Expected closing of the Merger in the third quarter of 2025.
• DURECT to file its quarterly report on Form 10-Q for the quarter ended June 30, 2025.

Key Dates

Recommendation

The tender offer has commenced at $1.75 per share, with potential milestone payments. For existing shareholders, holding shares to tender them into the offer is the logical next step to realize the upfront cash value and retain the potential for milestone payments. There is no immediate catalyst for a 'buy' recommendation as the acquisition price is largely set, and a 'sell' would mean missing out on the tender offer and potential milestones. The risks associated with the merger not closing or milestones not being achieved are present, but the current offer provides a clear path to liquidity and potential upside.

Keywords

DURECT, DRRX, Bausch Health, Acquisition, Merger, Tender Offer, Larsucosterol, Biopharmaceutical, Alcohol-associated Hepatitis, AH, Financial Results, Q2 2025, SEC Filing, 8-K, Clinical Development, Epigenetic Therapies